One of the most promising prognostic targets of cancer metastasis is MRPL4, with studies consistently demonstrating that increased expression is associated with a higher risk of metastasis in both breast and prostate cancer [24, 45, 46]. Here, MRPL4 is linked to prostate carcinoma.